HC Wainwright Increases Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for Gossamer Bio in a research note issued to investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.17) EPS.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million.

A number of other brokerages have also recently weighed in on GOSS. Wedbush reissued an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Friday, May 16th. The Goldman Sachs Group lifted their price target on Gossamer Bio from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, May 16th.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $1.20 on Monday. The business’s 50-day moving average price is $1.02 and its 200 day moving average price is $1.00. The firm has a market cap of $272.76 million, a P/E ratio of -3.75 and a beta of 1.82. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors have recently bought and sold shares of the stock. Graham Capital Management L.P. purchased a new position in Gossamer Bio in the 4th quarter worth about $32,000. Virtu Financial LLC acquired a new stake in Gossamer Bio during the 1st quarter worth about $38,000. Invesco Ltd. acquired a new stake in Gossamer Bio during the 1st quarter worth about $48,000. Fullcircle Wealth LLC acquired a new stake in Gossamer Bio during the 4th quarter worth about $43,000. Finally, Velan Capital Investment Management LP acquired a new stake in Gossamer Bio during the 4th quarter worth about $68,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.